Tollys closes Series A
financing of €2.3 million

Logo Tollys

Funds will further development of a new cancer immunotherapy:  synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors

Tollys

A new dimension in immuno-oncology

Office

41 quai Fulchiron
69005 Lyon, FRANCE

Contact us